Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Looking out for the blind spot.
Novel Insights and Therapeutics in Multiple Sclerosis.
[Emerging new disease--modifying therapies for multiple sclerosis].
A Cross-Sectional Examination of the Associations Between Symptoms, Community Integration, and Mental Health in Multiple Sclerosis.
Comparative Neuroregenerative Effects of C-Phycocyanin and IFN-Beta in a Model of Multiple Sclerosis in Mice.
The Ins and Outs of B Cells in Multiple Sclerosis.
Prevalence of Multiple Sclerosis in Tuscany (Central Italy): A Study Based on Validated Administrative Data.
Severe Hypomyelination and Developmental Defects Are Caused in Mice Lacking Protein Arginine Methyltransferase 1 (PRMT1) in the Central Nervous System.
Diagnostic work-up and therapeutic options in management of pediatric status epilepticus.
Can neurotrophic cytokines help to regenerate the mammalian central nervous system?
Anti-Aquaporin-1 Autoantibodies in Patients with Neuromyelitis Optica Spectrum Disorders.
Progression on the Multiple Sclerosis Functional Composite in multiple sclerosis: what is the optimal cut-off for the three components?
Fingolimod: A Review of Its Use in Relapsing-Remitting Multiple Sclerosis.
[Therapeutic development for neuromyelitis optica].
Myopathy associated with Neuromyelitis Optica Spectrum Disorders.
Convergence yet Continued Complexity: A Systematic Review and Critique of Health Economic Models of Relapsing-Remitting Multiple Sclerosis in the United Kingdom.
Cost-Effectiveness Analysis of Peginterferon Beta-1a In Italian Relapsing Remitting Multiple Sclerosis Management.
Ranking of Disease-Modifying Therapies for Multiple Sclerosis.
Risk factors of early onset of MS in women in reproductive age period: survival analysis approach.
Alemtuzumab for the treatment of multiple sclerosis.
Acute disseminated encephalomyelitis: an evaluation of 15 cases in childhood.
Astrocyte-specific activation of TNFR2 promotes oligodendrocyte maturation by secretion of leukemia inhibitory factor.
Expression of Kir4.1 and Kir5.1 inwardly rectifying potassium channels in oligodendrocytes, the myelinating cells of the CNS.
Identifying environmental antigens that activate myelin-specific T cells.
Three decades of drift: the misdiagnosis of predominantly neuropsychiatric multiple sclerosis.
Pages
« first
‹ previous
…
694
695
696
697
698
699
700
701
702
…
next ›
last »